Loading...
XSTOMCOVb
Market cap2.62bUSD
Dec 20, Last price  
192.40SEK
1D
0.63%
1Q
1.05%
IPO
201.80%
Name

Medicover AB

Chart & Performance

D1W1MN
XSTO:MCOVb chart
P/E
142.93
P/S
1.44
EPS
0.12
Div Yield, %
0.06%
Shrs. gr., 5y
2.34%
Rev. gr., 5y
21.06%
Revenues
1.75b
+15.64%
365,300,000415,600,000497,300,000580,200,000671,600,000844,400,000997,800,0001,377,400,0001,510,200,0001,746,400,000
Net income
18m
+49.15%
4,300,0007,500,0004,300,00018,700,00024,600,00022,500,00025,800,000101,800,00011,800,00017,600,000
CFO
205m
+20.45%
21,700,00028,700,00025,900,00050,300,00044,400,00087,300,000156,000,000216,700,000170,200,000205,000,000
Dividend
Apr 29, 20241.39622 SEK/sh
Earnings
Feb 07, 2025

Profile

Medicover AB (publ) provides healthcare and diagnostic services in Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It operates through two segment, Healthcare Services and Diagnostic Services. The company's diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company operates 97 clinical laboratories, 733 blood-drawing points, and 26 clinics in 10 countries; and 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. It serves corporate and private customers, and patients, as well as public payers. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.
URL
https://www.medicover.com/
IPO date
May 23, 2017
Employees
44,000
Domiciled in
SE
Incorporated in
SE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,746,400
15.64%
1,510,200
9.64%
1,377,400
38.04%
Cost of revenue
1,689,700
1,243,100
1,039,800
Unusual Expense (Income)
NOPBT
56,700
267,100
337,600
NOPBT Margin
3.25%
17.69%
24.51%
Operating Taxes
5,200
5,800
37,200
Tax Rate
9.17%
2.17%
11.02%
NOPAT
51,500
261,300
300,400
Net income
17,600
49.15%
11,800
-88.41%
101,800
294.57%
Dividends
(17,900)
(17,800)
(10,400)
Dividend yield
0.08%
0.09%
0.02%
Proceeds from repurchase of equity
(300)
BB yield
0.00%
Debt
Debt current
229,100
101,900
89,000
Long-term debt
1,213,400
1,262,400
1,021,500
Deferred revenue
86,700
Other long-term liabilities
137,800
87,200
(400)
Net debt
1,372,400
1,305,600
1,001,300
Cash flow
Cash from operating activities
205,000
170,200
216,700
CAPEX
(110,500)
(140,600)
(102,200)
Cash from investing activities
(119,800)
(184,800)
(333,600)
Cash from financing activities
(73,700)
(24,300)
164,100
FCF
(10,300)
70,700
77,900
Balance
Cash
64,400
49,100
277,900
Long term investments
5,700
9,600
(168,700)
Excess cash
40,330
Stockholders' equity
191,000
193,700
216,200
Invested Capital
1,669,800
1,512,500
1,343,870
ROIC
3.24%
18.30%
27.02%
ROCE
3.40%
17.18%
23.78%
EV
Common stock shares outstanding
149,652
148,717
148,351
Price
150.10
7.44%
139.70
-62.24%
370.00
125.61%
Market cap
22,462,821
8.12%
20,775,809
-62.15%
54,889,704
136.12%
EV
23,987,421
22,258,409
56,047,604
EBITDA
239,100
429,000
448,600
EV/EBITDA
100.32
51.88
124.94
Interest
51,400
34,500
20,100
Interest/NOPBT
90.65%
12.92%
5.95%